The Readout
A new Congress takes office in January, and it will have real power to act on health care costs and on the science and public health capabilities Americans rely on. In the Boston Globe, I laid out two priorities: lower the prices that drive health care spending, and protect American leadership in science. Nikki makes the case in TIME for keeping the CDC’s judgments independent of who holds the White House.
That principle matters beyond Washington. A researcher at a Russian anti-plague institute died in late September, and weeks later the world still cannot independently verify what happened. We need systems that can independently detect unusual biological activity, identify emerging threats, and give leaders the information they need to act. That’s what we’re building.
— Dr. Ashish Jha, Co-Founder & CEO
—
From the Field: Dallas, Texas
BioRadar is now built and running as a pilot in Dallas, with real-world data flowing into the platform. This first version is undergoing rapid improvement as we refine its capabilities and lay the groundwork for expansion to additional communities.
—
Founder POV: A Note from Nikki
The first question health officials ask about early-warning systems is often about false alarms. Individual signals, from wastewater sequencing to pharmacy sales and symptom searches, can be noisy. We look for corroboration across independent data sources to distinguish meaningful changes from routine variation.
The second question is what their staff should do with that information on a Tuesday morning. That's why BioRadar operates as a service, working with departments' existing data and workflows. We provide regular briefings on what changed and what to watch, and when a signal warrants attention, someone on our team calls someone on theirs.
— Dr. Nikki Romanik, Co-Founder & President
—
New Strategic Advisors
Detecting a biological threat is only half the problem. The data has to be reliable at the source, useful to the people who must act on it, and built into something they will use. Three new strategic advisors, each of whom has done one of those things before, are helping us pressure-test how we do it:
Dr. DJ Kleinbaum, co-founder of Emerald Cloud Lab, on running laboratory operations at scale with consistent, reproducible results.
Hon. Andy Weber, former Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense programs, with three decades in national security, on what officials responsible for deterrence, preparedness and response need from biological intelligence.
Dr. Daniel Widmaier, co-founder of Bolt Threads, on turning complex science into a product people can use.
They follow Dr. David Relman of Stanford and Dr. Kevin Esvelt of MIT, co-chairs of our Scientific Advisory Board. Read the Scientific Advisory Board announcement.
—
Team and Growth
Trapper Markelz joins as Chief Product Officer. Trapper has spent more than 25 years building software from idea to production and leads the platform that turns wastewater, syndromic, behavioral and open-source data into briefings for public health agencies. He previously served as CEO of MeYou Health and COO of Beamable.
Burt LaFountain joins as Chief Strategy Officer. Burt spent more than 16 years at Boston Consulting Group, where he was a Managing Director and Partner and a founding member of its applied AI practice. He earned his MBA at MIT Sloan.
Sofie Fox, MPH, joins as Head of Site Operations and Development. Sofie has a background in public health and biosecurity research and helped create COBRA, the largest public database of biothreat risk assessments. She holds an MPH from Northeastern University.
—
On the Record
When a researcher at a Russian anti-plague institute died in late September, national outlets turned to Ashish, the former White House COVID-19 Response Coordinator, as one of the experts to explain what was and wasn’t known. He also wrote about what should happen next. His point throughout: the world needs to verify events like this independently, and detect threats without depending on any one government’s account.
Boston Globe: Ashish on what the US should do after the Irkutsk death, from pressing Russia for specifics to funding detection that can flag pathogens nobody thought to test for.
The BMJ: Ashish calls for independent verification of what happened at the Irkutsk institute, and for international rules covering labs that work with dangerous pathogens.
STAT: Ashish on AI and biological threats: preventing misuse is critical, but it has to be paired with stronger systems to detect and respond.
CNN OutFront and NBC News: Ashish on the Irkutsk lab incident.
—
Where We'll Be
Nikki will be at INNOVATE ‘26 in Dallas on November 17. She will present a case study highlighting Dallas as an innovative leader in the new age of Biotechnology and Public Health with Dr. Philip Huang, Director of Dallas County Health and Human Services.
If you’ll be at INNOVATE, let us know and we’ll find time to talk. Request a Briefing.
—
Early warning only helps if people trust the information behind it. If you want to talk through how that works in your department…
Request a BriefingReply to this email and tell us what you’re seeing in your city. We read every response.